The DOI matches its Crossref record; 94 of the 95 references it cites were found in a registry or an index.
Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management
Open accessAbstract
Diarrhea is one of the main drawbacks for cancer patients. Possible etiologies could be radiotherapy, chemotherapeutic agents, decreased physical performance, graft versus host disease and infections. Chemotherapy-induced diarrhea (CID) is a common problem, especially in patients with advanced cancer. The incidence of CID has been reported to be as high as 50-80% of treated patients (≥30% CTC grade 3-5), especially with 5-fluorouracil bolus or some combination therapies of irinotecan and fluoropyrimidines (IFL, XELIRI). Regardless of the molecular targeted approach of tyrosine kinase inhibitors and antibodies, diarrhea is a common side effect in up to 60% of patients with up to 10% having severe diarrhea. Furthermore, the underlying pathophysiology is still under investigation. Despite the number of clinical trials evaluating therapeutic or prophylactic measures in CID, there are just three drugs recommended in current guidelines: loperamide, deodorized tincture of opium and octreotide. Newer strategies and more effective agents are being developed to reduce the morbidity and mortality associated with CID. Recent research focusing on the prophylactic use of antibiotics, budesonide, probiotics or activated charcoal still have to define the role of these drugs in the routine clinical setting. Whereas therapeutic management and clinical work-up of patients presenting with diarrhea after chemotherapy are rather well defined, prediction and prevention of CID is an evolving field. Current research focuses on establishing predictive factors for CID like uridine diphosphate glucuronosyltransferase-1A1 polymorphisms for irinotecan or dihydropyrimidine-dehydrogenase insufficiency for fluoropyrimidines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The resulting SN-38 in the gut lumen exhibits toxicity towards intestinal epithelial cells and is thought to exacerbate the diarrhea found in up to 80% of CRC patients50, 51.”
From The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism (2016) · cites this paper as [50]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 2×
“Irinotecan is frequently used in first- and second-line treatment of metastatic colorectal cancer [Saltz et al. 2000, 2007; Hurwitz et al. 2004; Jordan et al. 2004; Van Cutsem et al. 2009].”
Sorafenib in Advanced Hepatocellular Carcinoma
정, 재. (2008) · Cited by 5,586
Radiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115 · cited 1×
“However, there was no increase in toxicity of head and neck radiation by addition of cetuximab in a phase III trial despite a possible correlation between EGFR targeting and maturation of squamous eptithelium of the tongue and nasal cavity [Bonner et al. 2006; Keefe and Gibson, 2007].”
BackgroundCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 2×
“For monoclonal antibodies (mAb), such as the chimeric IgG1 mAb cetuximab or the fully human IgG2 mAb panitumumab, rates of grade 2 diarrhea are up to 21% and for grade 3 (ie greater than 7 stools per day or requiring intravenous fluids) between 1 and 2% [Van Cutsem et al. 2007; Davila and Bresalier, 2008; Vincenzi et…”
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647 · cited 2×
“…Everolimus and temsirolimus (inhibitors of the mammalian target of rapamycin [m-TOR]) were both recently approved for treatment of renal cell cancer, causing diarrhea in up to 40% with a rate of severe diarrhea in less than 5% of patients [Hudes et al. 2007; Motzer et al. 2008; Hess et al. 2009].”
BackgroundMotzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“…Everolimus and temsirolimus (inhibitors of the mammalian target of rapamycin [m-TOR]) were both recently approved for treatment of renal cell cancer, causing diarrhea in up to 40% with a rate of severe diarrhea in less than 5% of patients [Hudes et al. 2007; Motzer et al. 2008; Hess et al. 2009].”
BackgroundIrinotecan plus Fluorouracil and Leucovorin for Metastatic Colorectal Cancer
Saltz, L. B., Cox, J. V., Blanke, C., Rosen, L. S., Fehrenbacher, L., Moore, M. J., Maroun, J. A., Ackland, S. P., Locker, P. K., Pirotta, N., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009283431302 · Cited by 3,005 · cited 2×
“Irinotecan is frequently used in first- and second-line treatment of metastatic colorectal cancer [Saltz et al. 2000, 2007; Hurwitz et al. 2004; Jordan et al. 2004; Van Cutsem et al. 2009].”
BackgroundMotzer, R. J., Hutson, T. E., Tomczak, P., Michaelson, M. D., Bukowski, R. M., Oudard, S., Negrier, S., Szczylik, C., Pili, R., Bjarnason, G. A., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.1293 · Cited by 2,181 · cited 1×
“Multitargeting tyrosine kinase inhibitors Sorafenib and sunitinib cause diarrhea in 30 50% of patients (all grades) with a rate of less than 10% of grade 3 diarrhea [Llovet et al. http://tam.sagepub.com 55 2008; Gore et al. 2009; Motzer et al. 2009].”
BackgroundVan Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 1×
“…such as the chimeric IgG1 mAb cetuximab or the fully human IgG2 mAb panitumumab, rates of grade 2 diarrhea are up to 21% and for grade 3 (ie greater than 7 stools per day or requiring intravenous fluids) between 1 and 2% [Van Cutsem et al. 2007; Davila and Bresalier, 2008; Vincenzi et al. 2008].”
Background
Research works printed but not linked: 9
- Cao, S., 1998, Cancer Res, 58, 1695
- Dupont, H.L., 1997, Am J Gastroenterol, 92, 1962
- Engelking, C., 1998, Oncol Nurs Forum, 25, 859
- Kehrer, D.F., 2001, Clin Cancer Res, 7, 1136
- Rosenoff, S.H., 2006, J Support Oncol, 4, 289
- Siber, G.R., 1980, Cancer Res, 40, 3430
- Stringer, A.M., 2007, Experimental Biology and Medicine, 232, 96
- Trifan, O.C., 2002, Cancer Res, 62, 5778
- Voigt, W., 1998, Anticancer Res, 18, 3499
Cited by
Alleviating Cancer Drug Toxicity by Inhibiting a Bacterial Enzyme
Wallace, B. D., Wang, H., Lane, K. T., Scott, J. E., Orans, J., Koo, J. S., Venkatesh, M., Jobin, C., Yeh, L.-A., Mani, S., et al. (2010) · Science · doi:10.1126/science.1191175 · Cited by 1,080
Gut microbiota in colorectal cancer development and therapy
Wong, C. C., & Yu, J. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00766-x · Cited by 721
The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism
Spanogiannopoulos, P., Bess, E. N., Carmody, R. N., & Turnbaugh, P. J. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.17 · Cited by 717
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
“SN-38G’s secretion into the bile and subsequent deconjugation by beta-glucuronidase produced by the intestinal flora is strongly implicated in the enterohepatic recirculation of SN-38 and the delayed severe diarrhea observed with irinotecan [52].”
BackgroundThe emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target
Goldenberg, D. M., Stein, R., & Sharkey, R. M. (2018) · Oncotarget · doi:10.18632/oncotarget.25615 · Cited by 327
“com concentrations of SN-38G in the serum might explain this difference, since the re-circulation of SN-38G is suspected to be responsible for late diarrhea in IRI therapy [117, 118].”
Background
Metadata
- Authors
- Stein, A., Voigt, W., & Jordan, K.
- Affiliations
- Martin Luther University Halle-Wittenberg (DE)
- Corresponding author
- Stein, Alexander
- Venue
- Therapeutic Advances in Medical Oncology
- Publisher
- SAGE Publications
- Published
- 2009-12-04
- Volume
- 2
- Issue
- 1
- Pages
- 51-63
- ISSN
- 1758-8340 (ISSN-L)
- 1758-8359
- PMC
- PMC3126005
- OpenAlex
- W2125060052
- Cited by
- 431
- References
- 95
- Citations by year
- 2026: 30 · 2025: 44 · 2024: 30 · 2023: 39 · 2022: 37 · 2021: 35 · 2020: 38 · 2019: 30 · 2018: 36 · 2017: 28 · 2016: 14 · 2015: 22 · 2014: 26 · 2013: 11 · 2012: 5
- FWCI
- 4.15
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Therapeutic Advances in Medical Oncology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Dermatology › Chemotherapy-related skin toxicity
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- chemotherapy-induced diarrhea, pathophysiology, 5-fluorouracil, irinotecan, fluoropyrimidine, loperamide, octreotide, prophylaxis, budesonide, probiotics, activated carbon, antibiotic prophylaxis, UGT1A1 polymorphism, dihydropyrimidine dehydrogenase deficiency, predictive factors, chemotherapy side effects
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. https://app.cochat.ai/papers/10.1177/1758834009355164
- The paper
- Stein, A., Voigt, W., & Jordan, K. (2010). Review: Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Therapeutic Advances in Medical Oncology. https://doi.org/10.1177/1758834009355164
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.